Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Allogeneic HSCT for autoimmune disease: a shared decision

Autologous haematopoietic stem cell transplantation (HSCT) can be an effective treatment for refractory autoimmune diseases. With reports of the use of allogeneic HSCT emerging, how do these two very different types of stem cell transplantation compare and is allogeneic HSCT advisable?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout


  1. Greco, R. et al. Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMTR, ADWP, IEWP, and PDWP working parties. Front. Immunol. 10, 1570 (2019).

    Article  Google Scholar 

  2. Thomas, E. D. Pros and cons of stem cell transplantation for autoimmune disease. J. Rheum. 24 (Suppl. 48), 100–102 (1997).

    Google Scholar 

  3. Snowden, J. A. et al. Evolution, trends, outcomes and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 1, 2742–2756 (2017).

    Article  Google Scholar 

  4. Pasquini, M. et al. Transplantation for autoimmune diseases in North and South America: a report of the Center of International Blood and Marrow Transplant Research. Biol. Blood Marrow Transplant 18, 1471–1478 (2012).

    Article  Google Scholar 

  5. Sullivan, K. M. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N. Engl. J. Med. 378, 35–47 (2018).

    Article  Google Scholar 

  6. Silva, J. M. F. et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. Blood Adv. 2, 777–786 (2018).

    Article  CAS  Google Scholar 

  7. Schrezenmeier, H. et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 110, 1397–1400 (2007).

    Article  CAS  Google Scholar 

  8. Mielcarek, M. et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood 127, 1502–1508 (2016).

    Article  CAS  Google Scholar 

  9. Sarantopoulos, S., Cardones, A. R. & Sullivan, K. M. How I treat refractory chronic graft-versus-host disease. Blood 133, 1191–1200 (2019).

    Article  CAS  Google Scholar 

  10. Sullivan, K. M. et al. Shared decision-making in hematopoietic stem cell transplantation for sickle cell disease. Biol. Blood Marrow Transplant 24, 883–886 (2018).

    Article  Google Scholar 

Download references


K.M.S. and S.S. would like to thank members in the multidisciplinary team at Duke University Medical Center for their contributions in the care of patients with systemic sclerosis undergoing stem cell transplantation: G. Long, T. Helms and A. Adler, (at the Division of Hematologic Malignancies and Cellular Therapy); A. Shah and E. W. St Clair (at the Division of Rheumatology and Immunology); and A. R. Cardones (at the Department of Dermatology)

Author information

Authors and Affiliations


Corresponding author

Correspondence to Keith M. Sullivan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sullivan, K.M., Sarantopoulos, S. Allogeneic HSCT for autoimmune disease: a shared decision. Nat Rev Rheumatol 15, 701–702 (2019).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing